Loading stock data…
Vivani Medical (VANI)
$1.21+0.01 (+0.83%)
After Hours$1.19-0.02 (-1.63%)· Last close Jun 29
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vivani Medical, Inc. in the Healthcare sector is trading at $1.21 with a market capitalization of $104M. Wall Street consensus targets $3.83 (3 analysts), implying a +216.8% move over the next 12 months. The stock is currently 37% below its 52-week high of $1.92, remaining 7.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +216.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.82M↓ | -$6.81M↓ | -$6.72M↑ | -$7.46M↓ | -$6.56M |
| Net Income | -$6.78M↓ | -$6.63M↓ | -$6.53M↑ | -$7.14M↓ | -$6.30M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$103.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-141.93%
Volume
Today's trading volume
45,770
Recent News
Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the firm’s lowered target. The firm believes NPM-139 is uniquely positioned to potentially offer efficacy comparable to Wegovy while requiring only once or twice yearly administration, the analyst tells investors.Easter Sale - 70% Off TipRanksUnlock hedge fund-level
Vivani Medical: Q4 Earnings Snapshot
ALAMEDA, Calif. AP) — Vivani Medical, Inc. VANI) on Thursday reported a loss of $6.6 million in its fourth quarter.
Insiders Are Still Scooping Up Under Armour and WR Berkley Shares
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.